Juno Therapeutics Inc (JUNO) reported quarterly earnings results on Thursday, Aug-4-2016. The company reported $-0.64 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.59. The company posted revenue of $27.60 million in the period, compared to analysts expectations of $9.80 million. The company’s revenue was up 121.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.35 EPS.
Many Wall Street Analysts have commented on Juno Therapeutics Inc. Shares were Reiterated by FBR Capital on Jul 8, 2016 to “Outperform” and Lowered the Price Target to $ 61 from a previous price target of $73 .Shares were Downgraded by JP Morgan on Jul 8, 2016 to ” Neutral” and Lowered the Price Target to $ 39 from a previous price target of $63 .Raymond James Initiated Juno Therapeutics Inc on Jun 2, 2016 to “Outperform”, Price Target of the shares are set at $52.
Juno Therapeutics Inc closed down -0.18 points or -0.58% at $30.68 with 10,37,791 shares getting traded on Tusday. Post opening the session at $30.86, the shares hit an intraday low of $29.98 and an intraday high of $31.1 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 24, 2016, Richard Klausner (director) sold 12,000 shares at $40.71 per share price. According to the SEC, on Jun 21, 2016, Hyam Levitsky (EVP, Research & CSO) sold 12,418 shares at $42.98 per share price. On Jun 13, 2016, Steve Harr (CFO & Head, Corp. Development) sold 30,000 shares at $43.29 per share price, according to the Form-4 filing with the securities and exchange commission.
Juno Therapeutics Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates JCAR015 JCAR017 and JCAR014 utilize CAR technology to target CD19 a protein expressed on the surface of various B cell leukemias and lymphomas. Juno’s other product candidates include JCAR018: CD22 JCAR023: L1CAM (CD171) JCAR020: MUC-16 / IL-12 ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML myelodysplasic syndrome and chronic myeloid leukemia.